New Key to Cancer Cure: Checkpoint Inhibitor Therapy (C) (No CME)
This session has been identified and designated as Credit to Meet ACS Accreditation/Verification Requirements for Cancer.
This Panel Session will provide an update on recent Food and Drug Administration (FDA) approval of Programmed Death Receptor 1 Ligand (PD L1)-directed immunotherapy in Merkel cell carcinoma, and it will describe the implications of this advance for other solid tumors associated with viral etiologies.
- Lessons from Checkpoint Inhibitor Treatment of Merkel Cell Carcinoma
Howard L. Kaufman, MD, FACS, Boston, MA
- Advances in Immunotherapy of Anal Cancer
- Cathy Eng, MD, Houston, TX
- The Shifting Role of Surgical Management in the Era of Immuno-Oncology
Ken Tanabe, MD
- Practicing surgeons
- Apply new knowledge and ideas to improve their surgical practice
- Adapt concepts and quality measures in support of research advancements
- Enhance the quality of patient care
- For questions about the course content, please contact email@example.com.
- If you have any technical questions, contact firstname.lastname@example.org.
In accordance with the ACCME Accreditation Criteria, the American College of Surgeons must ensure that anyone in a position to control the content of the educational activity (planners and speakers/authors/discussants/moderators) has disclosed all relevant financial relationships with any commercial interest. For additional information, please visit the ACCME website: http://www.accme.org/requirements/accreditation-requirements-cme-providers/policies-and-definitions/financial-relationships-and-conflicts-interest
The ACCME also requires that ACS manage any reported conflict and eliminate the potential for bias during the educational activity. Any conflicts noted below have been managed to our satisfaction. The disclosure information is intended to identify any commercial relationships and allow learners to form their own judgments. However, if you perceive a bias during a activity, please report it on the evaluation.
(Download the full list of disclosures.)
Faculty and Disclosures
Howard L. Kaufman, MD, FACS, Boston, MA - Replimune, Inc.: Compensation: CMO
Robert L. Ferris, MD, Pittsburgh, PA -Amgen: Advisory Board, EMD Serono: Advisory Board, Astra-Zeneca/MedImmune: Advisory Board, Clinical Trial, Research Funding, Lilly: Advisory Board, PPD : Advisory Board (Benitec, Immunicum), Bristol-Myers Squibb: Advisory Board, Clinical Trial, Research Funding
Cathy Eng, MD, Houston, TX - Roche,Bayer,Sirtex,Merck: Speaker's Bureau, Advaxis, Roche, Forty-Seven: Research Grants
Kenneth K. Tanabe, MD, FACS - Helix12: Equity: Board of Directors, Cancer Experts Now: Consulting Fees: consultant on medical second opinions, Best Doctors: Consulting Fees: consultant on medical second opinions, Leidos: Consulting Fees: grant reviewer, American Cancer Society: Honoraria: Editor, UpToDate: Royalties: Editor
Program Committee and Disclosures
CHAIR: Henri R. Ford, MD, MHA, FACS, FAAP, FRCSEng(Hon), Miami, FL - No Disclosures
VICE-CHAIR: David T. Cooke, MD, FACS, Sacramento, CA - No Disclosures
David C. Borgstrom, MD, FACS, Morgantown, WV - No Disclosures
Daniel L. Dent, MD, FACS, San Antonio, TX - No Disclosures
Roger R. Dmochowski, MD, FACS, Nashville, TN - Allergen: Honoraria: Consultant
Audra A. Duncan, MD, FACS, London, ON - No Disclosures
Mariam F. Eskander, MD, Boston, MA - No Disclosures
Paula Ferrada, MD, FACS, Richmond, VA - No Disclosures
Neil H. Hyman, MD, FACS, Chicago, IL - No Disclosures
Martin S. Karpeh, Jr., MD, FACS, New York, NY - No Disclosures
Dennis H. Kraus, MD, FACS, New York, NY - No Disclosures
Kenneth W. Sharp, MD, FACS, Nashville, TN - No Disclosures
David A. Spain, MD, FACS, Stanford, CA - No Disclosures
Mary T. Hawn, MD, FACS, Stanford, CA - No Disclosures
Daniel M. Herron, MD, FACS, FASBMS, New York, NY - No Disclosures
Barbara Lee Bass, MD, FACS, FRCS(Hon), Houston, TX - No Disclosures
Quan-Yang Duh, MD, FACS, San Francisco, CA - No Disclosures
B. J. Hancock, MD, FACS, FRCSC, Winnipeg, MB - No Disclosures
Ronald V. Maier, MD, FACS, FRCSEd(Hon), Seattle, WA - No Disclosures
Valerie W. Rusch, MD, FACS, New York, NY - No Disclosures
A Certificate of Completion will be awarded.
This educational activity is not eligible for CME or CE credits
- 0.00 AMA PRA Category 1 Credit™
- 0.00 Certificate of Completion
- 0.00 Self Assessment Credit